Participated · Series A · Oct 2020

Primmune Therapeutics is a clinical-stage therapeutics company focused on designing and developing systemically acting, orally delivered small-molecule toll-like receptor 7 (TLR7) agonists. Its lead candidate, PRTX007, aims to stimulate the innate immune system and is being advanced for cancers and other diseases that respond to immunotherapy. The company plans to launch Study PRTX007-003, a Phase 2 neoadjuvant efficacy trial evaluating PRTX007 in combination with standard-of-care anti-PD-1 therapy for patients with Stage III resectable melanoma. Primmune’s approach could provide a convenient oral alternative to existing injectable immunotherapies. To date, the firm has raised at least $23.3 million in Series B funding, including the latest $8.6 million tranche. These funds will support the upcoming Phase 2 trial and continued development of its TLR7 agonist platform.

Participated · Series A · Nov 2019

AN2 Therapeutics is a clinical-stage biopharmaceutical company based in Menlo Park, CA, focused on developing novel therapies for rare, chronic, and serious infectious diseases. The company is developing epetraborole, a once-daily, orally administered investigational treatment for patients with chronic non-tuberculous mycobacterial lung disease (NTM). The recent financing is expected to support advancement of epetraborole through clinical development. AN2 is led by President and CEO Eric Easom. The company completed corporate governance changes alongside the raise, appointing Patricia Martin and Stephanie Wong to its board of directors. No operating metrics (revenue/users) were disclosed in the article. AN2 Therapeutics is a global health biopharmaceutical company based in Menlo Park, California, focused on the research, development and commercialization of novel medicines targeting infectious diseases. Its lead program is a clinical-stage antibacterial therapeutic agent described as having a novel mechanism-of-action, and the company also has several earlier-stage programs. AN2 intends to use the proceeds of its Series A financing to advance the lead clinical program and those earlier programs. The company is led by co-founder and CEO Eric Easom. AN2 announced a strategic partnership with Brii Biosciences under which Brii will obtain a license to develop, manufacture and commercialize AN2’s lead compound in greater China. The company positions itself as bringing modern biomedical and drug-development expertise to create transformational medicines for patients suffering from infectious diseases.